Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of subcutaneous ShK-186 in healthy volunteers
NL-OMON36904Phase 1Active, not recruiting
- Sponsor
- Kv1.3 Therapeutics
- Start
- Aug 2012
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, double-blind trial of dalazatide in autoimmune disease (7 cohorts), sponsored by Kv1.3 Therapeutics. Primary endpoints: Plasma drug concentrations, Pharmacokinetic parameters and 5 more. Started Aug 2012; status: active, not recruiting.
02
Drugs
dalazatide
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON36904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36904.